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Purpose: To evaluate the technical feasibility and toxicity of TomoDirect in breast cancer patients who received
radiotherapy after breast-conserving surgery.
Methods: 155 consecutive patients with breast carcinoma in situ or T1-2 breast cancer with negative lymph node
received breast irradiation with TomoDirect using simultaneous integrated boost technique in the prospective
cohort study. A radiation dose of 50.4 Gy and 57.4 Gy in 28 fractions was prescribed to the ipsilateral breast and
tumor bed, respectively. Dosimetric parameters of target and organ at risk and acute complication were assessed
prospectively.
Results: The mean dose for the tumor bed is 58.90 Gy. The mean values of V54.53Gy (95% of the prescribed dose), V63.14Gy
(110% of the prescribed dose), and V66.01Gy (115% of the prescribed dose) were 99.97%, 1.26%, and 0%, respectively. The mean
value of radiation conformality index was 1.01. The mean value of radical dose homogeneity index was 0.89. The
average dose irradiated to the ipsilateral lung, heart, and contralateral breast was 4.72 Gy, 1.09 Gy, and 0.19 Gy,
respectively. The most common toxicity was dermatitis. During breast irradiation, grade 2 and 3 dermatitis occurred
in 41 (26.5%) and 6 (3.9%) of the 155 patients, respectively. Two patients had arm lymphedema during breast
irradiation. Two patients had grade 2 pneumonitis 1 month after breast irradiation.
Conclusions: Radiotherapy using TomoDirect in early breast cancer patients showed acceptable toxicities and
optimal results in terms of target coverage and organ at risk sparing.
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Breast cancer is the frequently diagnosed cancer in
South Korea and it accounts for about 15% of all female
malignancies [1]. The annual incidence of breast cancer
has been gradually rising primarily due to increased
utilization of screening mammography. Breast-conserving
surgery and postoperative radiotherapy are basic treatment
modalities that have been widely used to manage early
breast cancer on the basis of the results of randomized
prospective trials [2]. The long-term survival rate among* Correspondence: koppul@catholic.ac.kr
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unless otherwise stated.women who undergo breast-conserving surgery followed
by breast irradiation is the same as that among women
who undergo radical mastectomy.
Conventional breast radiotherapy consists of 45 to
50 Gy of whole breast irradiation performed using two
tangential megavoltage photon beams and 10 to 16 Gy
of boost irradiation delivered to the tumor bed with
electron beams. Recently, techniques to improve the
accuracy of radiation delivery to the target have ad-
vanced. Helical TomoTherapy (Accuary, Sunnyvale,
CA), which can involve image-guided radiation therapy
(IGRT) using a megavoltage computed tomography
(CT) scan just prior to radiation treatment, is one specific
example of these advancements. TomoTherapy can also
yield intensity-modulated radiation therapy (IMRT) that. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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to the target and minimizes the irradiation to adjacent
dose-limiting organs. IMRT using TomoTherapy enables
the simultaneous delivery of different dose prescriptions
to different target volumes in the same treatment fraction.
This technique is called simultaneous integrated boost
(SIB). This modality is highly effective and safe in the
treatment of head and neck cancer by reducing the overall
treatment time and increasing the fraction size to boost
volumes [3].
In breast cancer patients, helical TomoTherapy is not
a suitable option since the gantry continuously rotates
around the patient, and this technique can deliver low-
dose radiation to lungs that is associated with an oc-
currence of radiation pneumonitis [4]. To avoid this
inefficiency of beam usage, a TomoDirect option using
static gantry positions combined with simultaneous
couch translation and dynamic collimator modulation
has been developed. In a pilot study, TomoDirect seemed
particularly well suited for postoperative irradiation in
breast cancer patients [5]. TomoDirect achieved an op-
timal target volume coverage and coincident adequate
normal tissue sparing in a dosimetric study [6].
Clinical studies of TomoDirect in breast cancer pa-
tients are scarce and have been assessed only in small
and retrospective series [5,6]. Thus, we undertook a
prospective study on the technical feasibility and toxicity
of TomoDirect in breast cancer patients who received
postoperative radiotherapy.
Methods
Patients
166 consecutive patients with breast carcinoma in situ
(pTisN0) or early breast cancer with negative axillary
node (pT1-2 N0) who underwent breast-conserving
surgery between January 2012 and February 2013 were
included in this prospective study. They received post-
operative radiotherapy with TomoDirect. The procedures
followed were in accordance with the ethical standards of
the responsible committee on human experimentation in
the Catholic University of Korea. Exclusion criteria were
metastatic breast cancer, previous radiation history of
chest wall due to the thoracic malignancy, and involved
resection margin.
Simulation and target volume contouring
During simulation, patients were immobilized in the
supine position using a foam cushion, which covered the
upper body and both arms. The patient’s arms were raised
above the head. A contrast-enhanced CT was scanned for
the treatment plan. CT imaging ranging from cervical to
lumbar vertebral body was obtained at 3-mm thicknesses
and was imported to the Pinnacle3 treatment planning
system (Philips Radiation Oncology Systems, Fitchburg,WI). The following structures were contoured: clinical
target volume (CTV), planning target volume (PTV),
and organ at risk (OAR). CTV1 is glandular tissue of the
breast. CTV2 is tumor bed cavity consisting of surgical
clips, postoperative change, and seroma. CTV was iden-
tified and contoured on the axial CT images. CTV was
consistently expanded by 6-mm radial and craniocaudal
margin to create the PTV with a constraint of reverse
expansion of 4 mm to the skin surface to avoid the poten-
tial skin toxicity [7]. Heart and lung were excluded from
the PTV when needed. The PTV provided a margin
around the CTV to compensate for the variability of
setup during breast irradiation and motion of breast or
chest with breathing. The OARs such as lung, heart,
and contralateral breast were contoured. For the IMRT
plan with TomoDirect, the raw dosimetric data set of
each patient was transferred from the Pinnacle3 treatment
planning system to the TomoTherapy Hi-Art version 4.0
planning system (Accuray, Sunnyvale, CA).
Dose prescription and constraint and planning
TomoDirect plan for a patient with early breast cancer is
shown in Figure 1. All patients were treated with the SIB
technique of TomoDirect. A radiation dose of 50.4 Gy in
28 fractions was prescribed to the PTV1, and a radiation
dose of 57.4 Gy in 28 fractions was prescribed to the
PTV2. Dose constraints for the PTV were: (1) ≥98% of the
PTV receives ≥95% of the prescribed dose and (2) ≤5% of
the PTV receives ≥110% of the prescribed dose. The dose
constraints for ipsilateral lung specified that the lung
should receive the mean dose of ≤10 Gy, 20% of the lung
was kept under 20 Gy, and 10% of the lung was kept
under 30 Gy. The dose constraints for heart specified that
10% of the heart was kept under 10 Gy and 5% of the
heart was kept under 20 Gy. Every effort was made to
decrease the irradiated volume of organs at risk such
as contralateral breast and lung as low as possible.
Dosimetric parameters to analyze target coverage and
dose distribution in the PTV were: (1) mean dose, (2)
VnGy, percentage of the volume receiving radiation ≥ n
Gy, (3) Dmin, minimum dose irradiated to the PTV, (4)
Dmax, maximum dose irradiated to the PTV, (5) Radiation
conformality index (RCI), PTV/V95% (volume enclosed by
the 95% of isodose line), and (6) Radical dose homogeneity
index (rDHI), Dmin/Dmax in the PTV. The irradiation to
the OARs, such as lung, heart, and contralateral breast,
were evaluated using values including mean dose and
VnGy. Two tangential beams with a jaw width of 2.5 cm
were used. The pitch value was set to the default value
one-tenth that of the field width (0.25 cm/projection for
the 2.5 cm beam). Beam angles were selected to minimize
dose to OARs and avoid irradiation to the contralateral
breast. To ensure that the prescribed dose was delivered
to the target, three leaves of the multi-leaf collimator were
Figure 1 (See legend on next page.)
Lee et al. Radiation Oncology 2014, 9:244 Page 3 of 7
http://www.ro-journal.com/content/9/1/244
(See figure on previous page.)
Figure 1 A breast cancer patient received breast irradiation with TomoDirect using simultaneous integrated boost technique after
breast-conserving surgery. A. TomoDirect could deliver radiation dose of 50.4 Gy (outline in yellow) to the breast and 57.4 Gy (outlined in pink)
in 28 fractions to the tumor bed at the same time. B. Beam’s eye view for the TomoDirect planning was digitally reconstructed using
beam-fluence data.
Table 1 Patient and treatment characteristics (n = 155)
Characteristic No. %
Age (year)
21-40 19 12.3
41-50 54 34.9
51-60 46 29.6
61-83 36 23.2
Site
Left 82 52.9
Right 73 47.1
T classification
pTis 52 33.5
pT1 84 54.1
pT2 19 12.4
N classification
Negative 155 100
Positive 0 0
Axillary lymph node dissection or sentinel
lymph node biopsy
103 66.4
Neoadjuvant or adjuvant chemotherapy 53 34.2
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pensated for the possible target movement by breathing
during irradiation.
Endpoint and toxicity assessment
The primary endpoint of the present study was to estimate
the dosimetric parameters of target coverage, homogen-
eity, and conformality and dose to organ at risk in breast
cancer patients who received postoperative radiotherapy
with TomoDirect. We also assess the fulfillment of dose
constraints for PTV and OAR. Dose violation within PTV
and OAR of 5.1% to 10% was considered a minor one
and greater than 10% was scored as a major one [8].
The secondary endpoint was to assess the acute compli-
cation. During the course of radiotherapy, patients were
evaluated weekly to assess acute toxicities. Patients were
also followed 1, 2 and 3 months after completion of
radiotherapy to assess radiation toxicities. Evaluation
consisted of clinical examination, complete blood counts,
and chest radiography at each visit. Adverse effects of
radiotherapy were assessed using the Common Termin-
ology Criteria for Adverse Events (version 3.0). Incidence
of toxicity grade ≥2 was recorded.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Results
166 consecutive patients with primary breast cancer or
carcinoma in situ who had received postoperative
radiotherapy using TomoDirect at our institution were
enrolled. Of the 166 patients, eleven patients were ex-
cluded from the study; two patients had a metastatic
disease and they received chemotherapy after breast
irradiation; nine patients had involved resection margins
and they received radiation dose of >57.4 Gy. Thus, the
remaining 155 patients were included for the final analysis
in the present study. The patient characteristics are shown
in Table 1. The median age of the patients was 51 years
(range, 20–83 years). They were all women. 52 (33.6%)
patients had carcinoma in situ lesions and 103 (66.4%)
patients had pT1-2 N0 lesions. Fifty-three (34.2%) pa-
tients received neoadjuvant (n = 12) or adjuvant chemo-
therapy (n = 53) before breast irradiation. All patients
received the prescribed doses of radiotherapy. There wereno unplanned interruptions in radiotherapy due to the
treatment toxicity.
Dose distribution of the planning target volume
The median of the PTV contoured in the 115 patients
was 345 cc (range, 135–845 cc) for PTV1 and 16 cc
(range, 8–67 cc) for PTV2. The TomoDirect plan met
the prescription requirements for the PTV in 154 (99.3%)
of 155 patients. In one patient with a huge breast (breast
volume, 845 cc), ≥98% of the PTV received 88% of the pre-
scribed dose so that ≤5% of the PTV can receive ≥110%
of the prescribed dose. The TomoDirect plan met the
prescription requirements for the ipsilateral lung and
heart in all cases. The median beam-on time for Tomo-
Direct was 175 seconds (range, 125–211 seconds). Dosi-
metric parameters for the PTV in the TomoDirect plan
are listed in Table 2. We used SIB technique using
TomoDirect in breast cancer. Since PTV 1 and PTV2
are not separate volumes, and PTV2 of tumor bed exists
within the PTV1 of normal breast. It is impossible to
keep the target dose guideline for the PTV1 which con-
tains the PTV2 due to the radiation build-up region near
the PTV2. Thus, we did not substrate the volume of
PTV1 from PTV2 and analyzed the dosimetric parameters
Table 2 Dosimetric parameters for the planning target
volume
Parameter Mean value
Mean dose (Gy) 58.90 ± 0.43
V54.5Gy (%) 99.97 ± 0.01
V60.2Gy (%) 9.19 ± 2.17
V63.1Gy (%) 1.26 ± 0.91
V66.0Gy (%) 0
Dmin (Gy) 54.25 ± 1.77
Dmax (Gy) 60.87 ± 0.91
RCI 1.01 ± 0.01
rDHI 0.89 ± 0.03
RCI radiation conformality index.
rDHI radical dose homogeneity index.
Dmin minimum dose irradiated to the planning target volume.
Dmax maximum dose irradiated to the planning target volume.
VnGy percentage of the volume receiving radiation ≥ n Gy.
Table 3 Dosimetric parameters for the organ at risk
Organ at risk Mean value
Ipsilateral lung
Mean dose (Gy) 4.72 ± 5.16
V50Gy (%) 0.93 ± 0.88
V40Gy (%) 3.57 ± 1.93
V30Gy (%) 5.33 ± 2.32
V20Gy (%) 7.23 ± 2.95
V10Gy (%) 9.42 ± 3.56
Heart
Mean dose (Gy) 1.09 ± 0.85
V50Gy (%) 0.11 ± 0.36
V40Gy (%) 0.31 ± 0.71
V30Gy (%) 0.54 ± 1.05
V20Gy (%) 0.87 ± 1.50
V10Gy (%) 1.21 ± 1.84
Contralateral breast
Mean dose (Gy) 0.19 ± 0.11
V50Gy (%) 0.04 ± 0.07
V40Gy (%) 0.08 ± 0.13
V30Gy (%) 0.17 ± 0.26
V20Gy (%) 0.25 ± 0.31
V10Gy (%) 0.42 ± 0.54
VnGy percentage of the volume receiving radiation ≥ n Gy.
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of PTV2 [4]. The mean dose for the PTV2 was
58.90 Gy. The mean of V54.5Gy (95% of the prescribed dose) and
V63.1Gy (110% of the prescribed dose) was 99.97% and 1.26%,
respectively. The average RCI value was 1.01 and
V66.01Gy (115% of the prescribed dose) value was zero.
Average Dmin and Dmax value was 54.25 Gy and
60.87 Gy, respectively. Average rDHI value was 0.89.
Avoidance of organs at risk
Table 3 shows the irradiated dose to the organs at risk,
which included the ipsilateral lung, heart, and contralat-
eral breast. The mean dose for the ipsilateral lung, heart,
and contralateral breast was 4.72 Gy, 1.09 Gy, and
0.19 Gy, respectively. We investigated the dosimetric pa-
rameters of the ipsilateral lung, which is the most critical
organ in breast cancer patients who receive postoperative
breast irradiation. The mean V50Gy and V40Gy values of ip-
silateral lung for high-dose irradiation with TomoDirect
were <5%, and the mean V20Gy and V10Gy values for low-
dose irradiation were 7.23% and 9.42%, respectively. The
mean V10-50Gy values for the heart and contralateral breast
were <1%.
Early treatment toxicity
Grade 2 or higher acute toxicities observed during treat-
ment and after irradiation are listed in Table 4. No grade
4 toxicity occurred in this study. No grade 2 or higher
hematologic adverse effect developed. The most common
non-hematologic toxicity was dermatitis. During breast ir-
radiation, grade 2 and 3 dermatitis occurred in forty one
(26.5%) and six (3.9%) of the 155 patients, respectively.
One patient who committed a minor violation of target
dose had grade 2 dermatitis without other acute toxicities.
There was no significant difference between six patients(3.9%) with grade 3 dermatitis and others in term of mean
PTV dose, RCI, and rDHI. All skin problems were re-
covered with conservative managements. Two patients
already had arm lymphedema after breast-conserving
surgery and adjuvant chemotherapy, and the symptom
of arm lymphedema was persistent during breast irradi-
ation and follow-up. Two patients had grade 2 pneumon-
itis one month after breast irradiation and were cured
with steroid treatment.
Discussion
Helical TomoTherapy, which enabled simultaneous IMRT
and IGRT, has achieved encouraging clinical outcomes in
terms of tumor response, survival, and toxicity in head
and neck and prostate cancer [9,10]. However, it is not
easy to apply continuously-rotating TomoTherapy to
breast cancer patients, since it is accompanied by low-
dose irradiation on both lungs and can result in radiation
pneumonitis [11].
TomoDirect, which uses static gantry positions, com-
bined with simultaneous couch translation and multi-leaf
collimator modulation makes it possible to irradiate the
whole breast without low-dose radiation to lungs in breast
cancer patients. The static gantry angles of TomoDirect
are identical to the tangential beam angles of conventional
Table 4 Acute treatment toxicity of breast irradiation
using TomoDirect
Complication Grade
2 3 4
Number (percent) of patients
Hematologic
Leucopenia 0 0 0
Anemia 0 0 0
Thrombocyopenia 0 0 0
Non hematologic
Dermatitis 41 (26.5) 6 (3.9) 0
Radiation pneumonitis 2 (1.3) 0 0
Pericarditis 0 0 0
Arm lymphedema 2 (1.3) 0 0
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and conventional 3-dimensional conformal radiotherapy
(3DCRT) is that the patient is stationary during breast
irradiation using the conventional linear accelerator and
the patient slides through the intensity-modulated beam
during breast irradiation using TomoDirect. Reynders
et al. assessed the dosimetric parameters of TomoDirect
and 3DCRT. Compared with conventional radiotherapy,
TomoDirect provided an adequate PTV coverage with a
significant reduction of high-dose radiation to the OAR
[5]. In our prospective study, TomoDirect achieved perfect
target dose coverage in all patients except one patient with
a large breast: ≥98% of the PTV received ≥95% of the pre-
scribed dose and ≤5% of the PTV received ≥110% of the
prescribed dose. None received <115% of the prescribed
dose to the PTV. The conformality of TomoDirect irradi-
ation was good with an average RCI value of 1.01 and the
homogeneity of TomoDirect irradiation was favorable
with an average rDHI value of 0.89. The TomoDirect op-
tion enables specified beam angles, reducing planning
time of IMRT compared with helical TomoTherapy.
Moreover, the beam-on time of TomoDirect during breast
irradiation is less than helical TomoTherapy and compar-
able to that of 3DCRT [6]. In our study, median beam-on
time was just 175 seconds. These considerations could
make TomoDirect a useful option in the radiation oncology
department which only equipped with helical TomoTher-
apy without conventional linear accelerator.
The radiation dose delivered to the organs at risk, such
as the ipsilateral lung, heart, and contralateral breast,
was evaluated by dosimetric values of mean dose and
V10-50Gy. The incidence of moderate to severe radiation
pneumonitis after radiotherapy ranges from 0% to 37%
[12]. This wide variation reflects the different types of
radiotherapy and the presence or absence of neoadjuvant
or adjuvant chemotherapy, which may influence the risk ofradiation pneumonitis. The risk of radiation pneumonitis
seems to increase as the cumulative dose of radiation to
the normal lung tissue increases, and the mean lung dose
and V20Gy are considered reliable dosimetric predictors
for the occurrence of radiation pneumonitis [13]. A mean
lung dose <10 Gy and V20Gy <20% is associated with the
radiation pneumonitis probability of <3% [14]. In our trial,
dosimetric values for the ipsilateral lung were mean dose
of 4.72 Gy, V20Gy of 7.23%, and V30Gy of 5.33%, and only
two patients (1.3%) had grade 2 radiation pneumonitis
one month after breast irradiation using TomoDirect.
Whole breast irradiation after breast-conserving surgery
is sometimes accompanied by radiation-induced heart
injury. Especially, the pericardium near the tangential
photon beam is a vulnerable area for radiation damage.
The dose-volume relationship and mean dose for the
heart is significantly associated with radiation-induced
heart disease [15]. According to the quantitative ana-
lysis of normal tissue effect in the clinic (QUANTEC)
review, V25 < 10% correlates with a long-term cardiac
mortality <1%, an overly safe risk estimate based on model
predictions [13]. The dose–response relationship for
pericarditis was suggested by the QUANTEC review,
and predicted that mean dose <26 Gy and V30 < 46%
corresponded to a pericarditis probability of <15%. In
our study, mean radiation dose for the heart was just
1.09 Gy and V30 and V20 values were <1%. Thus, in our
trial no patient had radiation-induced heart disease
during breast irradiation and 3 months after the end of
breast irradiation.
The occurrence of contralateral breast carcinoma
after breast irradiation has been extensively investigated.
Scattered radiation beams certainly reached the oppos-
ite breast, and this could bring about theoretical car-
cinogenesis on the contralateral breast. However, there
was no distinct evidence that scattered radiation during
breast irradiation was significantly associated with the
occurrence of contralateral breast cancer. In a case–
control study including a cohort of 41,109 women diag-
nosed with breast cancer, the risk of a second cancer in
the opposite breast was significantly increased among
women who underwent irradiation at a relatively young
age (<45 years) [16]. However, Fisher et al. reported that
the risk for an event of contralateral breast cancer
among a group treated with lumpectomy and irradi-
ation, as compared with the total-mastectomy group,
was not significantly different in the 20-year follow-up
of a randomized trial [2]. In another study, there was no
statistically significant difference of the 20-year crude
cumulative incidence for contralateral breast cancer be-
tween breast-conserving surgery and radiation versus
mastectomy groups [3]. In our trial, TomoDirect deliv-
ered a mean dose of 0.19 Gy to the contralateral breast
and V10–50 values were all <0.5%. Thus, this scattered
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cinogenic [17,18].
Although our trial showed very favorable results for
target coverage and normal tissue sparing with Tomo-
Direct in early breast cancer patients, we acknowledge
that our trial had a number of limitations. First, our
study should be understood in view of the inherent biases
of a short-term follow-up design. We did not evaluate
chronic adverse effects. Second, we did not evaluate the
recurrence and survival outcome due to the short-term
follow up. Thus, we do not suggest that TomoDirect using
SIB in early breast cancer is as effective as conventional
breast irradiation in terms of survival and recurrence. For
the clear-cut assessment of long-term complication such
as the occurrence of contralateral breast cancer, recur-
rence, and survival, a follow-up time exceeding 10 years is
required.
SIB technique using TomoDirect in early breast cancer
patients showed acceptable toxicity profiles and optimal
results in terms of target coverage and normal tissue
sparing. Survival, tumor recurrence, and concerns for
the risk of contralateral breast carcinoma due to scattered
radiations during breast irradiation must be evaluated
through a long-term follow-up study.
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